Gustavo Leal
Researcher in psychiatry and neuropsychopharmacology at the Universidade Federal da Bahia / Hospital Universitário Professor Edgard Santos
Data updated
Papers
Trials
Research Footprint
Gustavo Leal appears in 5 tracked papers (2017–2023), most studied alongside Ketamine and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Intravenous arketamine for treatment-resistant depression: open-label pilot study (257 citations).
Frequent co-authors: Acioly Luiz Tavares Lacerda, Gerard Sanacora and Colleen Loo.
Background & Research
Gustavo C. Leal appears as an author on several clinical studies of ketamine, esketamine, and arketamine for treatment-resistant depression, including randomized, open-label, and retrospective designs. PubMed affiliations on these papers place him in neuropsychopharmacology and psychiatry groups associated with the Universidade Federal da Bahia in Salvador, Brazil, and in some studies he is linked to Stanford University via coaffiliation contexts.
Key Impact
He is a notable clinical ketamine/esketamine researcher with multiple human studies on arketamine, esketamine, and treatment-resistant depression.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →